Loading...
•
Dec 31, 2024
Neurocrine Biosciences Q4 2024 Earnings Report
Key Takeaways
Neurocrine Biosciences reported strong Q4 2024 results with total revenue of $627.7 million, driven by INGREZZA sales growth of 23%. The company saw increased R&D and SG&A expenses related to pipeline expansion and new product launches.
Revenue by Segment
Forward Guidance
Neurocrine expects continued revenue growth in 2025, driven by increased sales of INGREZZA and newly launched CRENESSITY. R&D and SG&A expenses will rise due to expanded pipeline investments.
Positive Outlook
- INGREZZA sales expected to continue strong growth.
- CRENESSITY launch adds a new revenue stream.
- Advancement of pipeline with new Phase 3 trials.
- Strong cash position supports expansion.
- Strategic collaboration with Takeda enhances development capabilities.
Challenges Ahead
- Increased R&D expenses impact profitability.
- Higher SG&A costs due to product launches.
- Stock-based compensation expenses continue to rise.
- Potential competitive pressure on INGREZZA pricing.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...